Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
Eledon announced updated results from an investigator-initiated trial of tegoprubart in 12 Type 1 Diabetes patients undergoing islet transplantation at UChicago Medicine. All 12 patients achieved insulin independence and maintained HbA1c levels below 6.5%, with a mean of 5.4%, representing a 2.6% improvement from baseline. The study reported zero severe hypoglycemic episodes and zero rejection events, avoiding the nephrotoxicity and other side effects associated with standard calcineurin inhibitor regimens like tacrolimus.
Key figures
- Drug Name
- tegoprubart
- Patient count
- 12
- Mean hba1c post
- 5.4%
- Hba1c improvement
- 2.6%
- Rejection episodes
- 0
- Max follow up months
- 22
- Median follow up months
- 8
- Insulin independence rate
- 100%
- Severe hypoglycemia events
- 0
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.